Sarah B. Goldberg

Also affiliated with Yale University, Medical Oncology Hematology Consultants

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 7%percentile

0.109Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Lung Cancer(2023)10.1016/j.lungcan.2023.107423

Top 72%

0.109DataRank

Top 72%1 citations

Chih–Yuan Hsu, Jennifer G. Whisenant, Melina E. Marmarelis, Carolyn J. Presley, Karen L. Reckamp +24 more

Papers

Driven by 24 papers — median percentile 28. Top paper: “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial”.

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30111-x

N/A

6.6DataRank · unranked

541 citations

Kurt A. Schalper, Scott Gettinger, Amit Mahajan, Roy S. Herbst, Anne C. Chiang +19 more

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Cancer Research(2020)10.1158/0008-5472.can-19-3819

N/A

2.8DataRank · unranked

61 citations

Alexis Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy Nagelberg +19 more

Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease

NeuroImage(2022)10.1016/j.neuroimage.2022.119228

N/A

1.6DataRank · unranked

69 citations

Patrick H. Luckett, Brian A. Gordon, Tammie L.S. Benzinger, Suzanne E. Schindler, Anne M. Fagan +87 more

Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease

JAMA Neurology(2022)10.1001/jamaneurol.2021.5181

N/A

1.2DataRank · unranked

37 citations

Paul Maruff, Nicolas R. Barthélemy, Alison Goate, Jason Hassenstab, Chihiro Sato +87 more

Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Cancer Discovery(2023)10.1158/2159-8290.cd-22-1420

N/A

0.787DataRank · unranked

189 citations

Haniel A. Araújo, Giuseppe Lamberti, Alissa J. Cooper, Neal S. Akhave, Teng Zhou +61 more

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Nature(2024)10.1038/s41586-024-07943-7

N/A

0.769DataRank · unranked

168 citations

Haniel A. Araújo, Minh Truong, Yu Qian, Xin Sun, Ana Galán‐Cobo +95 more

Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer

Journal of Thoracic Oncology(2023)10.1016/j.jtho.2023.10.001

N/A

0.617DataRank · unranked

60 citations

Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu +11 more

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR -Mutant NSCLC (SWOG S1403)

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0741

N/A

0.606DataRank · unranked

56 citations

Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst +7 more

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations

Nature Communications(2022)10.1038/s41467-022-34398-z

N/A

0.584DataRank · unranked

48 citations

David Lu, Michael J. Grant, Steven E. Stayrook, Manali Phadke, Zenta Walther +6 more

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.01.012

N/A

0.571DataRank · unranked

44 citations

So Yeon Kim, Jacqueline V. Aredo, Jamie Feng, Frances A. Shepherd, Chao Xu +52 more

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3497

N/A

0.564DataRank · unranked

42 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz +16 more

Residual circulating tumor DNA (ctDNA) after two months of therapy to predict progression-free and overall survival in patients treated on S1403 with afatinib +/- cetuximab.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9532

N/A

0.552DataRank · unranked

9 citations

Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick +6 more

Brain network decoupling with increased serum neurofilament and reduced cognitive function in Alzheimer’s disease

Brain(2023)10.1093/brain/awac498

N/A

0.515DataRank · unranked

30 citations

Jeremy F. Strain, Patricia K. Mansfield, Jiaxin Cindy Tu, Aaron Tanenbaum, Oliver Preische +85 more

Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer

Clinical Lung Cancer(2020)10.1016/j.cllc.2020.11.006

N/A

0.457DataRank · unranked

20 citations

Ramsey Yusuf, Lydia Barakat, Michael Virata, Geliang Gan, Yanhong Deng +5 more

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

Pigment Cell & Melanoma Research(2022)10.1111/pcmr.13059

N/A

0.425DataRank · unranked

16 citations

Maya Dimitrova, Kevin Kleffman, Christopher Alvarez‐Breckenridge, Michael B. Atkins, Adrienne Boire +22 more

Integrative multiomics reveals common endotypes across PSEN1, PSEN2, and APP mutations in familial Alzheimer’s disease

Alzheimer s Research & Therapy(2025)10.1186/s13195-024-01659-6

N/A

0.406DataRank · unranked

14 citations

Andrew B. Caldwell, Qing Liu, Michael Q. Fitzgerald, Srinivasan Ramachandran, Celeste M. Karch +95 more

A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.9060

N/A

0.208DataRank · unranked

3 citations

Mary W. Redman, Jennifer M. Suga, Tareq Al Baghdadi, John L. Villano, Sarah B. Goldberg +6 more

Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Lung Cancer(2023)10.1016/j.lungcan.2023.107423

Top 72%

0.109DataRank

Top 72%1 citations

Chih–Yuan Hsu, Jennifer G. Whisenant, Melina E. Marmarelis, Carolyn J. Presley, Karen L. Reckamp +24 more

Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9121

N/A

0.104DataRank · unranked

1 citations

Frederick H. Wilson, Sarah B. Goldberg, Anne C. Chiang, Brian S. Henick, Elin Rowen +10 more

The design of the Dashboard Activated Services and Telehealth for Heart Failure (DASH-HF) study: A pragmatic quality improvement randomized implementation trial for patients with heart failure with reduced ejection fraction

Contemporary Clinical Trials(2022)10.1016/j.cct.2022.106895

N/A

0.104DataRank · unranked

1 citations

Gregg C. Fonarow, Jeffrey J. Hsu, Cynthia A. Jackevicius, Freny Vaghaiwalla Mody, Omid Amidi +9 more

Association of alterations in multiple tumor suppressor genes with poor outcomes in patients with EGFR-mutant lung cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9104

N/A

0.104DataRank · unranked

1 citations

Michael J. Grant, Anna Wurtz, Giorgia Foggetti, Francisco Expósito, Jianlei Gu +7 more

Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.11155

N/A

0DataRank · unranked

0 citations

Jessica B. Long, John Rothen, Sida Huang, Pamela R. Soulos, Timothy J. Robinson +9 more

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Journal of Clinical Oncology(2024)10.1200/jco.23.02668

N/A

0DataRank · unranked

49 citations

Emily Miao, Lillian A. Boe, Tejas Patil, Brandon S. Imber, Nathaniel J. Myall +19 more

Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21112

N/A

0DataRank · unranked

0 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Anna Wurtz, Zofia Piotrowska, Andrew J. Piper‐Vallillo +13 more

Sarah B. Goldberg

Indexed papers

Top data-sharing exemplar

Papers